BioSniper ranking
Highest BioSniper Signature Score
The BioSniper Signature Score is a transparent, 0–10 composite built entirely from structured fundamentals — cash runway, financial health, pipeline maturity, pipeline breadth, catalyst momentum, and insider signal — with no LLM in the number and every dimension traceable to its underlying fields. This ranking surfaces the highest-scoring companies with adequate data coverage.
- Ranked entities
- 100
- Freshness
- No verified data date available
- Method
- Published source data
Prepared research question
Why is Merit Medical Systems Inc. — Highest BioSniper Signature Score → MMSI in this position, and what could change the ranking?
Traceable citations · Unknowns marked
- 1Merit Medical Systems Inc.MMSI · Oncology9.7 / 104 of 6 signals
- 2Erasca, Inc.ERAS · Oncology9.3 / 103 of 6 signals
- 3Mereo BioPharma Group plcMREO · Oncology9.3 / 103 of 6 signals
- 4Immunocore Holdings plcIMCR · Oncology9.2 / 103 of 6 signals
- 5PFIZER INCPFE · Oncology9.2 / 105 of 6 signals
- 6ABBOTT LABORATORIESABT · Oncology9.1 / 105 of 6 signals
- 7Eikon Therapeutics Inc.EIKN · Oncology9.1 / 103 of 6 signals
- 8MAIA Biotechnology, Inc.MAIA · Oncology9.1 / 105 of 6 signals
- 9Novartis AGNVS · Oncology9.0 / 104 of 6 signals
- 10Arcturus Therapeutics Holdings Inc.ARCT · Oncology8.9 / 103 of 6 signals
- 11PROTHENA CORP PUBLIC LTD COPRTA · Oncology8.9 / 104 of 6 signals
- 12TENAX THERAPEUTICS, INC.TENX · Neurology8.9 / 104 of 6 signals
- 13Viatris IncVTRS · Oncology8.9 / 105 of 6 signals
- 14Corvus Pharmaceuticals, Inc.CRVS · Oncology8.8 / 104 of 6 signals
- 15TScan Therapeutics, Inc.TCRX · Oncology8.8 / 103 of 6 signals
- 16Vanda Pharmaceuticals Inc.VNDA · Oncology8.8 / 104 of 6 signals
- 17BIOGEN INC.BIIB · Oncology8.7 / 106 of 6 signals
- 18Journey Medical CorpDERM · Oncology8.7 / 104 of 6 signals
- 19Protalix BioTherapeutics, Inc.PLX · Rare Disease8.7 / 103 of 6 signals
- 20PALATIN TECHNOLOGIES INCPTN · Rare Disease8.7 / 103 of 6 signals
- 21Faeth Therapeutics, Inc.FTH · Oncology8.6 / 104 of 6 signals
- 22Kailera Therapeutics, Inc.KLRA · Metabolic8.6 / 104 of 6 signals
- 23Sarepta Therapeutics, Inc.SRPT · Oncology8.6 / 104 of 6 signals
- 24Akari Therapeutics PlcAKTX · Oncology8.5 / 103 of 6 signals
- 25AYTU BIOPHARMA, INCAYTU · Oncology8.5 / 104 of 6 signals
- 26CUMBERLAND PHARMACEUTICALS INCCPIX · Rare Disease8.5 / 104 of 6 signals
- 27Dogwood Therapeutics, Inc.DWTX · Neurology8.5 / 103 of 6 signals
- 28MEDICINOVA INCMNOV · Oncology8.5 / 103 of 6 signals
- 29Actinium Pharmaceuticals, Inc.ATNM · Oncology8.4 / 103 of 6 signals
- 30Kiora Pharmaceuticals Inc.KPRX · Oncology8.4 / 103 of 6 signals
- 31Globus Medical Inc.GMED8.3 / 104 of 6 signals
- 32IDEAYA Biosciences, Inc.IDYA · Oncology8.2 / 104 of 6 signals
- 33Innoviva, Inc.INVA · Infectious Disease8.2 / 104 of 6 signals
- 34Novo Nordisk A/SNVO · Oncology8.2 / 103 of 6 signals
- 35ASTRAZENECA PLCAZN · Oncology8.1 / 105 of 6 signals
- 36IN8BIO, INC.INAB · Oncology8.1 / 103 of 6 signals
- 37Profound Medical Corp.PROF · Oncology8.1 / 103 of 6 signals
- 38Solid Biosciences Inc.SLDB · Rare Disease8.1 / 103 of 6 signals
- 39SELLAS Life Sciences Group, Inc.SLS · Oncology8.1 / 103 of 6 signals
- 40Zimmer Biomet Holdings Inc.ZBH · Oncology8.1 / 104 of 6 signals
- 41Aldeyra Therapeutics, Inc.ALDX · Oncology8.0 / 104 of 6 signals
- 42Annexon, Inc.ANNX · Oncology8.0 / 104 of 6 signals
- 43Baxter International Inc.BAX · Oncology8.0 / 103 of 6 signals
- 44BRISTOL MYERS SQUIBB COBMY · Oncology8.0 / 105 of 6 signals
- 45Cabaletta Bio, Inc.CABA · Neurology8.0 / 103 of 6 signals
- 46Coherus Oncology, Inc.CHRS · Oncology8.0 / 103 of 6 signals
- 47GE HealthCare Technologies Inc.GEHC · Oncology8.0 / 106 of 6 signals
- 48Incyte Corp.INCY · Oncology8.0 / 106 of 6 signals
- 49MiMedx Group IncMDXG · Oncology8.0 / 103 of 6 signals
- 50NANOVIRICIDES, INC.NNVC · Oncology8.0 / 103 of 6 signals
- 51Oncotelic Therapeutics, Inc.OTLC · Oncology8.0 / 104 of 6 signals
- 52ADMA BIOLOGICS, INC.ADMA · Oncology7.9 / 104 of 6 signals
- 53CATALYST PHARMACEUTICALS, INC.CPRX · Oncology7.9 / 105 of 6 signals
- 54Lantheus Holdings, Inc.LNTH · Oncology7.9 / 104 of 6 signals
- 55Rein Therapeutics, Inc.RNTX · Rare Disease7.9 / 104 of 6 signals
- 56VERTEX PHARMACEUTICALS INC / MAVRTX · Oncology7.9 / 105 of 6 signals
- 57Anika Therapeutics Inc.ANIK · Pain7.8 / 104 of 6 signals
- 58Cogent Biosciences, Inc.COGT · Oncology7.8 / 103 of 6 signals
- 59Kalaris Therapeutics, Inc.KLRS · Oncology7.8 / 104 of 6 signals
- 60MediWound Ltd.MDWD · Metabolic7.8 / 103 of 6 signals
- 61OPKO HEALTH, INC.OPK · Oncology7.8 / 104 of 6 signals
- 62ZEVRA THERAPEUTICS, INC.ZVRA · Rare Disease7.8 / 105 of 6 signals
- 63Aardvark Therapeutics, Inc.AARD · Rare Disease7.7 / 103 of 6 signals
- 64Altimmune, Inc.ALT · Oncology7.7 / 104 of 6 signals
- 65Amylyx Pharmaceuticals, Inc.AMLX · Rare Disease7.7 / 104 of 6 signals
- 66Coya Therapeutics, Inc.COYA · Oncology7.7 / 103 of 6 signals
- 67ELUTIA INC.ELUT · Cardiovascular7.7 / 103 of 6 signals
- 68Entera Bio Ltd.ENTX · Oncology7.7 / 103 of 6 signals
- 69HYPERION DEFI, INC.HYPD · Ophthalmology7.7 / 105 of 6 signals
- 70Jade Biosciences, Inc.JBIO · Immunology7.7 / 103 of 6 signals
- 71NextCure, Inc.NXTC · Oncology7.7 / 103 of 6 signals
- 72Rallybio CorpRLYB · Oncology7.7 / 103 of 6 signals
- 73SpyGlass Pharma Inc.SGP · Ophthalmology7.7 / 103 of 6 signals
- 74SYNLOGIC, INC.SYBX · Rare Disease7.7 / 104 of 6 signals
- 75Treace Medical Concepts Inc.TMCI · Oncology7.7 / 104 of 6 signals
- 76Tyra Biosciences, Inc.TYRA · Oncology7.7 / 103 of 6 signals
- 77Vir Biotechnology, Inc.VIR · Oncology7.7 / 104 of 6 signals
- 78Xencor IncXNCR · Oncology7.7 / 104 of 6 signals
- 79AbbVie Inc.ABBV · Oncology7.6 / 105 of 6 signals
- 80ASSEMBLY BIOSCIENCES, INC.ASMB · Oncology7.6 / 104 of 6 signals
- 81Avalyn Pharma Inc.AVLN · Immunology7.6 / 104 of 6 signals
- 82Fulcrum Therapeutics, Inc.FULC · Oncology7.6 / 104 of 6 signals
- 83IMMUNIC, INC.IMUX · Neurology7.6 / 103 of 6 signals
- 84PLIANT THERAPEUTICS, INC.PLRX · Oncology7.6 / 103 of 6 signals
- 85PERRIGO Co plcPRGO · Oncology7.6 / 103 of 6 signals
- 86Voyager Therapeutics, Inc.VYGR · Rare Disease7.6 / 103 of 6 signals
- 87AbCellera Biologics Inc.ABCL · Oncology7.5 / 104 of 6 signals
- 88Ascendis Pharma A/SASND · Oncology7.5 / 104 of 6 signals
- 89Damora Therapeutics, Inc.DMRA · Oncology7.5 / 104 of 6 signals
- 90Inmune Bio, Inc.INMB · Oncology7.5 / 103 of 6 signals
- 91Moleculin Biotech, Inc.MBRX · Oncology7.5 / 104 of 6 signals
- 92UNITED THERAPEUTICS CorpUTHR · Oncology7.5 / 105 of 6 signals
- 93Zenas BioPharma, Inc.ZBIO · Neurology7.5 / 105 of 6 signals
- 94Bausch Health Companies Inc.BHC · Oncology7.4 / 105 of 6 signals
- 95Denali Therapeutics Inc.DNLI · Rare Disease7.4 / 104 of 6 signals
- 96Elanco Animal Health IncELAN · Immunology7.4 / 103 of 6 signals
- 97Filana Therapeutics Inc.FLNA · Oncology7.4 / 104 of 6 signals
- 98GYRE THERAPEUTICS, INC.GYRE · Immunology7.4 / 104 of 6 signals
- 99Jazz Pharmaceuticals plcJAZZ · Oncology7.4 / 105 of 6 signals
- 100Keros Therapeutics, Inc.KROS · Oncology7.4 / 104 of 6 signals
Ranked by the BioSniper Signature Score (0–10 average of up to 6 structured-data dimensions). Companies with fewer than 3 scored dimensions are excluded to avoid thin-coverage noise.
Frequently asked questions
How is the BioSniper Signature Score calculated?
It averages up to six 0–10 dimensions derived purely from structured data: cash runway, financial health, pipeline maturity, pipeline breadth, catalyst momentum, and insider signal. There is no language model in the number — each dimension traces to specific data fields.
What does data coverage mean for the score?
A dimension with no underlying data shows N/A rather than a fake zero, and the composite is only computed when enough dimensions are scorable — so a high score reflects genuine coverage, not a lucky single metric.
Is the Signature Score investment advice?
No. It is a transparent, structured-data summary meant for research and comparison, not a recommendation. Every input is inspectable so you can disagree with it.
From ranked signal to decision rule
Decide how this ranking should affect your thesis
Turn the ranking field into a criterion, add your own thresholds, and require supporting company evidence before it influences a decision.